Pfiz­er said Tues­day that the month­ly in­jec­tion that was one of the cor­ner­stones of its $10 bil­lion buy­out of Met­sera al­lowed obe­si­ty pa­tients to lose up to 10.5% of their weight, on a place­bo-ad­just­ed ba­sis, af­ter just over six months.

Share­hold­ers were unim­pressed with the da­ta, ap­pear­ing to doubt whether the re­sults were good enough to vin­di­cate Pfiz­er’s ac­qui­si­tion of the obe­si­ty-fo­cused biotech. Pfiz­er’s shares PFE were down 3% in ear­ly trad­ing, on the same day it re­port­ed its full-year 2025 earn­ings.

Now the main ques­tion for Pfiz­er is whether Tues­day’s re­sults jus­ti­fy the enor­mous in­vest­ment it is putting in­to its plans for no few­er than 10 Phase 3 tri­als for the as­set, named PF-08653944, or PF‘3944 for short.

Pfiz­er took a write-down on one of its re­cent high-pro­file ac­qui­si­tions while re­port­ing a pos­i­tive read­out from an­oth­er.

The phar­ma gi­ant said on Tues­day it took a $4.4 bil­lion im­pair­ment charge re­lat­ed in part to its $43 bil­lion ac­qui­si­tion of Seagen in 2023. The cen­ter­piece of that deal, Pad­cev, has re­port­ed strong sales. But an­oth­er as­set, disi­ta­m­ab ve­dotin, is be­ing "de­pri­or­i­tized," Pfiz­er said as part of its fourth-quar­ter earn­ings call Tues­day.

CFO Dave Den­ton dis­closed the charges in his pre­pared re­marks ahead of a call with in­vestors Tues­day, and said they were “re­lat­ed to sev­er­al med­i­cines in de­vel­op­ment as well as in-line prod­ucts.”

Ac­curEd­it Ther­a­peu­tics, a start­up based in Suzhou, Chi­na, has raised $75 mil­lion in Se­ries A fund­ing to ad­vance its grow­ing pipeline of CRISPR-based med­i­cines — among the largest rounds on record for a Chi­nese gene edit­ing com­pa­ny.

The fund­ing, which has­n't pre­vi­ous­ly been re­port­ed by West­ern me­dia, closed in Sep­tem­ber, Ac­curEd­it con­firmed to End­points News. The in­vest­ment brings to­tal fund­ing to $116 mil­lion since Ac­curEd­it's found­ing in 2021.

While the full sum may be small by US stan­dards, Ac­curEd­it — like many oth­er Chi­nese biotech star­tups — is al­ready prov­ing it can do more with less.

In an ex­clu­sive in­ter­view with End­points, founder and CEO Yongzhong Wang said Ac­curEd­it has al­ready test­ed CRISPR ther­a­pies for two car­dio­vas­cu­lar dis­eases — transthyretin amy­loi­do­sis and fa­mil­ial hy­per­c­ho­les­terolemia — in about 40 pa­tients. Da­ta from Ac­curEd­it pre­sent­ed last year sug­gest ef­fi­ca­cy and safe­ty are on par with, and per­haps slight­ly bet­ter than, those of sim­i­lar ther­a­pies be­ing de­vel­oped by com­pa­nies in the US.

Ul­tragenyx out­lined new da­ta on Tues­day that it hopes will con­vince the FDA to ap­prove its re­cent­ly re­sub­mit­ted rare dis­ease gene ther­a­py.

Among 17 pa­tients with San­fil­ip­po syn­drome type A who re­ceived the ther­a­py, cog­ni­tion scores on a mea­sure­ment of chil­dren’s de­vel­op­men­tal progress im­proved by an av­er­age of 23.2 points com­pared to nat­ur­al his­to­ry da­ta.

That dif­fer­ence — high­ly sta­tis­ti­cal­ly sig­nif­i­cant with a p-val­ue of p<0.0001 — could end up be­ing the new cen­ter­piece o